Techpool Bio-Pharma Co., Ltd. clinical trials
Acquired by Shanghai Pharmaceuticals Holding Co., Ltd, Aug 21, 2018 · source ↗
The registry lists 5 studies whose lead sponsor is Techpool Bio-Pharma Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 23, 2018.
Before and after it joined Shanghai Pharmaceuticals Holding Co., Ltd
- First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- 5
- First submitted after Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Techpool Bio-Pharma Co., Ltd.5 studies
Something wrong with this grouping? Tell us on the Shanghai Pharmaceuticals Holding Co., Ltd page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All Shanghai Pharmaceuticals Holding Co., Ltd studies →
- Post-market Safety Reassessment of Ulinastatin for InjectionStatus unknownNCT02520570
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)Status unknownNCT02895191Phase 2
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- Ulinastatin in Severe Acute PancreatitisSuspendedNCT01132521Phase 4
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart SurgeryStatus unknownNCT02527811Phase 4
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd
- The Study to Reevaluate the Safety and Efficacy of Human Urinary KallikreinStatus unknownNCT02562183Phase 4
Sponsor listed in the registry: Techpool Bio-Pharma Co., Ltd. · First submitted before Techpool Bio-Pharma Co., Ltd. became part of Shanghai Pharmaceuticals Holding Co., Ltd